// App-Quantinova.ai

5075 : Updated results: A phase I/IIa randomized trial of radium-223 + docetaxel versus docetaxel in patients with castration-resistant prostate cancer and bone metastases.

Researchers

Presenter

  • Michael J. Morris

Principal Investigators

  • Yohann Loriot

  • Christopher Sweeney

  • Karim Fizazi

  • Charles J. Ryan

  • Daniel H. Shevrin

  • Emmanuel S. Antonarakis

  • John Reeves

  • Kumari Chandrawansa

  • Martin Kornacker

  • Celestia S. Higano

Medical Centers

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

  • Institut Gustave Roussy, University of Paris Sud, Villejuif, France

  • Dana-Farber Cancer Institute, Harvard Cancer Center, Boston, MA

  • UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA

  • NorthShore University Health System, Evanston Hospital Kellogg Cancer Center, Evanston, IL

  • The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins, Baltimore, MD

  • Pharmaceuticals Division of Bayer, Whippany, NJ

  • Bayer Pharma AG, Berlin, Germany

  • University of Washington, Fred Hutchinson Cancer Research Center, Seattle Cancer Care Alliance, Seattle, WA

Locations

  • United States

  • Germany

  • France

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Metastatic castration-resistant prostate cancer

  • Bone metastases

  • Prostate cancer

  • Solid malignancies

Biomarkers

  • Alkaline phosphatase

  • Prostate specific antigen

Drug/Treatment

  • Radium-223 Dichloride

  • Docetaxel

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • I/II

Study Id's

  • NCT01106352

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved